Clinical trials: Locally Advanced Colorectal Cancer
Colorectal Cancer
Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00086931
- Testing
- capecitabine, oxaliplatin, conventional surgery
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer
Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study aims to evaluate the clinical efficacy and safety of anlotinib in combination with penpulimab and conventional chemoradiotherapy for the neoadjuvant treatment of locally advanced rectal cancer
- Trial name
- LARC-nCR01 (NCT06853769)
- Testing
- Anlotinib hydrochloride,Penpulimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Locally Advanced Rectal Cancer
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial
Seamless phase I/II trial with phase I part for determination of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1) with an experimental arm with…
- Trial name
- NCT04177602
- Testing
- Trifluridine/tipiracil chemoradiation, Capecitabine based chemoradiation
- Where
- 8 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Rectal Cancer, Radiotherapy
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
This study is a prospective phase II clinical trial aimed at exploring the potential benefits of supplementing β-hydroxybutyrate with existing short course radiotherapy sequential immunotherapy and CAPEOX therapy.
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy, Chemotherapy
- Trial name
- NCT07239466
- Testing
- Short-course radiotherapy, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tao Zhang
Lung Cancer (Locally Advanced or Metastatic), Pancreas Cancer, Metastatic
Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI
The study should evaluate the biological distribution of 99mTc-HYNIC-FAPI in metastatic cancer patients.
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Pancreas Cancer, Metastatic, Breast Cancer (Locally Advanced or Metastatic), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07457541
- Testing
- [99mTc]Tc-HYNIC-FAPI
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Rectal Cancer
Leucine Plus Radiochemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Colorectal cancer (CRC), a prevalent gastrointestinal malignancy, is experiencing a rising incidence in China. Rectal cancer constitutes nearly half of all new CRC cases, with over half of these patients diagnosed at a locally…
- Trial name
- NCT07359989
- Testing
- Oral administration of Leucine
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
This is a prospective, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of allogeneic natural killer (NK) cell injection combined with standard maintenance therapy in patients with locally…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07551778
- Testing
- NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy
- Volunteers
- 42 people
- Sponsor
- BOE Technology Group Co., Ltd.
Rectal Cancer
Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure
In a retrospective study, the investigators will compare patients with locally advanced rectal cancer with high risk factors for failure who were treated with standard therapy or with total neoadjuvant therapy.
- Trial name
- NCT04679597
- Testing
- Capecitabine
- Volunteers
- 161 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Cancer
A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer
This is an open-label, randomized phase II study. Patients will be randomly assigned to either FL or TS-1/irinotecan preoperative chemotherapy regimens by stratification.
- Trial name
- NCT01269216
- Testing
- 5-FU with leucovorin, TS-1 with Irinotecan
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Yonsei University
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Rectal Cancer
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Patients diagnosed with locally advanced very low rectal cancer were chosen to participate in a comprehensive neoadjuvant therapy (TNT) protocol.
- Trial name
- TRACE-LE (NCT05969847)
- Testing
- split-course hypofraction radiotherapy, CAPOX, Envafolimab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- 池畔
Locally Advanced Rectal Cancer
Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence
The purpose of this study is to identify the most promising treatment sequence in total neoadjuvant therapy for locally advanced rectal cancer with a high risk of recurrence.
- Trial name
- ICONA (NCT05054959)
- Testing
- Consolidation CAPOX Chemotherapy, Induction CAPOX Chemotherapy
- Where
- Slovenia
- Volunteers
- 62 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Cancer
Additional Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
The aim of this study is to evaluate the efficacy and safety of additional neoadjuvant chemotherapy with capecitabine during the resting periods in patients with locally advanced rectal cancer.
- Trial name
- NCT01671683
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Chungnam National University
Colorectal Cancer
Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
Phase 2A study, assessing the antitumor activity and the safety profile of GM102, a new compound (monoclonal antibody), administered alone or in combination with chemotherapy in patients with locally advanced or metastatic…
- Trial name
- NCT03799731
- Testing
- GM102, Trifluridine/Tipiracil, GM102 expansion
- Where
- 5 sites in Belgium, Czechia
- Volunteers
- 65 people
- Sponsor
- GamaMabs Pharma
Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial aims to assessing the efficacy and safety of neoadjuvant chemoradiation plus Tislelizumab (PD-1 inhibitor) with or without Probio-M9 and subsequent TME surgery, by…
- Conditions
- Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
- Trial name
- NCRIT-PM9 (NCT07458529)
- Testing
- CRT+PD-1 inhibitor+Probio-M9
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Seventh Medical Center of PLA General Hospital
Rectal Neoplasm Malignant
Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer
Background: Colorectal cancer is the leading cause of cancer-related deaths in Taiwan, with rectal cancer accounting for approximately 27% of all cases.
- Trial name
- NCT06831669
- Testing
- Collecting biospecimens
- Where
- Taiwan
- Volunteers
- 250 people
- Sponsor
- Chang Gung Memorial Hospital
Resectable Rectal Cancer Clinical Stage II and III
Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer
A Phase II study aimed to evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced resectable rectal cancer.
- Trial name
- NCT01152710
- Testing
- Capecitabine
- Where
- Slovenia
- Volunteers
- 57 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Cancer
A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer
Background: Neoadjuvant chemoradiotherapy (CRT) and total mesorectum excision (TME) has become the standard therapy for the treatment of locally advanced rectal cancer (LARC) to reduce the local recurrence rate, however, no…
- Trial name
- NCT03245203
- Testing
- FOLFIRI+beacizumab, CRT
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Total Neoadjuvant Treatment, Chemoradiotherapy
Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors
Purpose:To compare the efficacy and the safety of total neoadjuvant chemotherapy + TME with standard neoadjuvant concurrent chemoradiotherapy + TME + adjuvant chemotherapy for locally advanced rectal cancer patients with high…
- Conditions
- Total Neoadjuvant Treatment, Chemoradiotherapy, Local Advanced Rectal Cancer, High Risk Factors
- Trial name
- TNTCRT (NCT03177382)
- Testing
- Total neoadjuvant treatment, concurrent chemoradiotherapy, TME
- Where
- 2 sites in China
- Volunteers
- 458 people
- Sponsor
- West China Hospital
ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
- Conditions
- ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
- Trial name
- NCT07540572
- Testing
- IDE574, Fulvestrant injection
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences